{"id":295381,"date":"2013-02-14T10:29:21","date_gmt":"2013-02-14T04:59:21","guid":{"rendered":"http:\/\/stockviz.biz\/index.php\/?p=295381"},"modified":"2013-02-14T10:35:16","modified_gmt":"2013-02-14T05:05:16","slug":"analysis-auropharma","status":"publish","type":"post","link":"https:\/\/stockviz.biz\/index.php\/2013\/02\/14\/analysis-auropharma\/","title":{"rendered":"Analysis: AUROPHARMA"},"content":{"rendered":"<p>Today\u2019s pick is AUROPHARMA [stockquote]AUROPHARMA[\/stockquote]. The stock spent half of the year in a channel between Rs. 100 and Rs. 140. It broke out bullishly in August, and saw its 52 week high of Rs. 200 in January. Since then the stock has been moving downwards. In the last three months, the stock has moved <b>+2<strong>%<\/strong><\/b> vs. +6% of the Nifty\u2019s.<\/p>\n<p><a title=\"AUROPHARMA technical analysis chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=AUROPHARMA\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"AUROPHARMA technical analysis chart\" alt=\"AUROPHARMA technical analysis chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/02\/STOCK.AUROPHARMA2013-02-14.png\" width=\"602\" height=\"482\" border=\"0\" \/><\/a><\/p>\n<p>Oscillator <a href=\"http:\/\/stockviz.biz\/index.php\/part-ix-relative-strength-index-rsi\/\">RSI<\/a> and <a href=\"http:\/\/stockviz.biz\/index.php\/technical-trading\/chande-momentum-oscillator\/\">CMO<\/a> are closing in towards the over-sold territory. The stock is trading in the lower end of a very compact <a title=\"Bollinger Band\" href=\"http:\/\/stockviz.biz\/index.php\/2012\/07\/27\/bollinger-bands\/\">Bollinger band<\/a> giving no directional<b> <\/b>bias. Short-term technical just saw 9&#215;4 <b>bearish <\/b>cross-over.<\/p>\n<p>The <a href=\"http:\/\/stockviz.biz\/index.php\/part-xi-moving-average-convergence-divergence-macd2\/\">MACD<\/a> line is closing and the signal line are moving parallel to each other, unable to give any outlook. Also, Long-term and short-term <a href=\"http:\/\/stockviz.biz\/index.php\/technical-trading\/guppy-multiple-moving-averages\/\">GMMA<\/a> lines are running close to each other and are not giving out any directional<b> <\/b>bias.<\/p>\n<p><a title=\"AUROPHARMA correlation chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=AUROPHARMA\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"AUROPHARMA correlation chart\" alt=\"AUROPHARMA correlation chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/02\/cor.AUROPHARMA2013-02-14.png\" width=\"630\" height=\"210\" border=\"0\" \/><\/a><\/p>\n<p>AUROPHARMA\u2019s average <a href=\"http:\/\/stockviz.biz\/index.php\/tag\/correlation\/\">correlation<\/a> with the <a href=\"http:\/\/stockviz.biz\/Technicals.aspx?INDEX=NIFTY\">Nifty<\/a> is <b>+0.48<\/b> which is <b>positive<\/b>. The scrip will be replicating movement of Nifty. [stockquote]NIFTYBEES[\/stockquote]<\/p>\n<p><a title=\"AUROPHARMA volatility chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=AUROPHARMA\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"AUROPHARMA volatility chart\" alt=\"AUROPHARMA volatility chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/02\/Vol.AUROPHARMA2013-02-14.png\" width=\"630\" height=\"210\" border=\"0\" \/><\/a><\/p>\n<p>AUROPHARMA has a historical <a href=\"http:\/\/stockviz.biz\/index.php\/2012\/07\/17\/understanding-volatility-part-i\/\">volatility<\/a> in the range of 0.4 to 1.2. The scrip\u2019s volatility is currently in the lower end of the range.<\/p>\n<p>Given these technicals, we suggest a short-term<b> sell<\/b>. For the long-term we suggest to watch out for a directional expansion of the GMMA lines.<\/p>\n<h6 class=\"zemanta-related-title\" style=\"font-size: 1em\">Related articles<\/h6>\n<ul class=\"zemanta-article-ul zemanta-article-ul-image\" style=\"margin: 0px;padding: 0px;overflow: hidden\">\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/bhushanpundlikshirude.wordpress.com\/2013\/01\/01\/aurobindo-pharma-gains-on-usfda-nod-for-rizatriptan-benzoate-tablets\/\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/138826912_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/bhushanpundlikshirude.wordpress.com\/2013\/01\/01\/aurobindo-pharma-gains-on-usfda-nod-for-rizatriptan-benzoate-tablets\/\" target=\"_blank\">Aurobindo Pharma gains on USFDA nod for Rizatriptan Benzoate Tablets<\/a><\/li>\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=251849126\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/134227443_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=251849126\" target=\"_blank\">Aurobindo Pharma gets USFDA nod for Nafcillin injections<\/a><\/li>\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=251811109\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/133754008_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=251811109\" target=\"_blank\">Aurobindo Pharma gets USFDA nod for nausea injections<\/a><\/li>\n<\/ul>\n<div class=\"zemanta-pixie\" style=\"height: 15px;margin-top: 10px\"><img decoding=\"async\" class=\"zemanta-pixie-img\" style=\"border: currentColor;float: right\" alt=\"\" src=\"http:\/\/img.zemanta.com\/pixy.gif?x-id=4112c27c-a53e-4f24-81c5-7c175459a447\" \/><\/div>\n<div class=\"roundedCornerSmall\" style=\"height: 200px;padding-bottom: 0px;padding-left: 10px;width: 100%;padding-right: 0px;padding-top: 0px;border: grey 1px solid\">\n<div style=\"margin-top: 70px;float: left\"><a style=\"font-family: segoe ui;color: black;font-size: 18px;font-weight: 600\" href=\"http:\/\/stockviz.biz\/index.php\/2012\/11\/29\/the-stockviz-demat-account-2\/\">Open a StockViz Demat Account today!<\/a><\/div>\n<div style=\"float: right\"><a href=\"918026650232\"><img decoding=\"async\" style=\"border-width: 0px\" alt=\"call us qr code\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/web-static\/QR_CODE_DIRECT_CALL_634909979709728491.png\" \/><\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Today\u2019s pick is AUROPHARMA [stockquote]AUROPHARMA[\/stockquote]. The stock spent half of the year in a channel between Rs. 100 and Rs. 140. It broke out bullishly in August, and saw its 52 week high of Rs. 200 in January. Since then the stock has been moving downwards. In the last three months, the stock has moved &hellip; <\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[161,815],"class_list":["post-295381","post","type-post","status-publish","format-standard","hentry","category-your-money","tag-auropharma","tag-technical-analysis","entry"],"_links":{"self":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/295381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/comments?post=295381"}],"version-history":[{"count":0,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/295381\/revisions"}],"wp:attachment":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/media?parent=295381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/categories?post=295381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/tags?post=295381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}